DELCATH TO REPORT 2013 FOURTH QUARTER AND FULL YEAR RESULTS ON MARCH 12, 2014
February 25 2014 - 4:05PM
NEW YORK,
NY - February 25, 2014 - Delcath Systems, Inc. (NASDAQ:
DCTH) today announced that it will host a conference call and
webcast on Wednesday, March 12, 2014 at 4:30 p.m. ET to discuss its
financial results for the fourth quarter and full year of 2013
ended December 31, 2013, and provide an update on recent corporate
progress.
The dial-in numbers for the
conference call are 800-706-7749 (U.S. participants) and
617-614-3474 (international participants); both numbers require
passcode 27241849. To access the live webcast, go to the Events
& Presentations page on the Investor Relations section of the
Company's website at http://www.delcath.com/investors/events/.
A taped replay of the call will be
available beginning approximately two hours after the call's
conclusion and will be available for seven days. Dial-in numbers
for the replay are 888-286-8010 and 617-801-6888 for U.S. and
International callers, respectively. The replay passcode for both
U.S. and International callers is 49674508. An archived
webcast will also be available at
http://www.delcath.com/investors/events/.
About
Delcath Systems
Delcath Systems, Inc. is a specialty pharmaceutical and medical
device company focused on oncology. Our proprietary drug/device
combination product, the Delcath Hepatic Delivery System, is
designed to administer high dose chemotherapy and other therapeutic
agents to the liver, while controlling the systemic exposure of
those agents. The Company's initial focus is on the treatment of
primary and metastatic liver cancers. Outside of the United States,
our proprietary product to deliver and filter melphalan
hydrochloride is marketed under the trade name Delcath Hepatic
CHEMOSAT® Delivery System for melphalan hydrochloride. The Company
obtained authorization to affix a CE Mark for the Generation Two
CHEMOSAT Delivery System for Melphalan in April 2012. The right to
affix the CE mark allows the Company to market and sell the
CHEMOSAT Delivery System for Melphalan in Europe. The Delcath
Hepatic Delivery System for Melphalan has not been approved for
sale in the United States by the United States Food and Drug
Administration. The Company has initiated plans to investigate
Melphalan Hydrochloride for Injection for use with the Delcath
Hepatic Delivery System for primary liver cancer
Private Securities Litigation Reform Act of 1995
provides a safe harbor for forward-looking statements made by the
Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating
to: the ability of hospitals in Germany to successfully
negotiate and receive reimbursement for the CHEMOSAT procedure in
their region under Value 4 status and the amount of reimbursement,
if any, to be provided under Value 4 status
in 2014, approval of Individual Funding Requests for reimbursement
of the CHEMOSAT procedure, the impact of Value 4 status on
potential CHEMOSAT product use and sales in Germany, the Company's
ability to regain compliance with the NASDAQ Marketplace Rules and
maintain its listing on the NASDAQ Capital market, the timing and
results of future clinical trials including without limitation the
HCC trials, clinical adoption, use and resulting sales, if any, for
the CHEMOSAT system to deliver and filter melphalan in Europe, our
ability to successfully commercialize the chemosaturation system
and the potential of the chemosaturation system as a treatment for
patients with primary and metastatic disease in the liver, our
ability to obtain reimbursement for the CHEMOSAT system in various
markets, the Company's ability to satisfy the requirements of the
FDA's Complete Response Letter and provide the same in a timely
manner, approval of the current or future chemosaturation system
for delivery and filtration of melphalan, doxorubicin or other
chemotherapeutic agents for various indications in the US and/or in
foreign markets, actions by the FDA or other foreign regulatory
agencies, our ability to successfully enter into strategic
partnership and distribution arrangements in foreign markets and
the timing and revenue, if any, of the same, uncertainties relating
to the timing and results of research and development projects,,
and uncertainties regarding our ability to obtain financial and
other resources for any research, development, clinical trials and
commercialization activities. These factors, and others, are
discussed from time to time in our filings with the Securities and
Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. We undertake no obligation to publicly update or revise
these forward-looking statements to reflect events or circumstances
after the date they are made
Contact Information: |
Investor Contact: |
Media Contact: |
Michael Polyviou/Patty Eisenhaur |
John Carter |
EVC Group |
EVC Group |
212-850-6020/951-316-0577 |
646-201-5431 |
###
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Delcath Systems, Inc via Globenewswire
HUG#1764589